Avidity Biosciences 2021 Corporate Presentation

Avidity Biosciences is developing a new class of targeted RNA therapies using its proprietary AOC (Antibody Oligonucleotide Conjugate) platform to treat serious diseases. The company is in the early stage of development with preclinical and discovery-stage programs, focusing on leveraging its platform to create products of commercial value.